Traders News Source a Leading Small Cap Research and Corporate Access Firm, would like to welcome you to one of the most successful trading groups in the market. Below we are offering an exclusive report on the cannabis industry that could provide significant gains going forward.
Projected Sector Growth for Medical Marijuana
Why 22nd Century Group (NYSE-MKT: XXII)? Because they hold the PATENTS!
22nd Century Group, Inc. (NYSE MKT: XXII), is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding.
Marijuana & Hemp
Cannabis sativa (marijuana, hemp) has been used for millennia as a source of fiber, food (oil and protein), medicine and as a recreational psychoactive drug. According to the Global Hemp Group, the industrial global hemp market is currently estimated to be about $800 million and will easily grow to be a several billion-dollar market within 5 years with a sufficient expansion of supply.
22nd recently announced its research collaboration with strategic partner Anandia Laboratories, Inc. in Vancouver, Canada, has resulted in new industrial hemp plants that have zero tetrahydrocannabinol (THC), the principal psychoactive component in cannabis. Anandia Labs is a Health Canada licensed company focused exclusively on cannabis breeding and testing.
U.S. Federal law requires hemp crops get tested for THC levels. Crops containing above 0.3% THC must be destroyed. 22nd Century has developed a solution to this problem by creating industrial hemp plants that contain zero THC.
The Company’s wholly-owned subsidiary, Botanical Genetics LLC has approved an additional investment of approximately $800,000 in further cannabis research with Anandia Labs. The Company’s continued investment in Anandia Labs will be product-oriented and will focus on developing a range of next generation industrial hemp plants that contain optimized levels of important cannabinoids such as CBD, CBC, and CBG.
22nd Century will provide these proprietary hemp plants to the Company’s university research partners for optimization in various climates around the world. THC-free cannabis is an ideal agricultural crop and an excellent source of medically important cannabinoids; 22nd Century has the exclusive rights to commercialize the plants arising from this collaborative project in the United States. Again, this is patent protected technology that XXII owns.
This successful cannabinoid research at Anandia Labs is the result of one of many of the Company’s research activities relating to industrial hemp plants and to the extraction of medically-important cannabinoids for medical research. In conducting research in this field, Botanical Genetics operates its own laboratories in New York and collaborates with third-party research universities, commercial laboratories, and hemp/cannabis growers that possess all necessary licenses and permits to conduct their activities. 22nd Century currently owns or exclusively controls more than 200 issued patents and more than 50 pending patent applications (http://patft.uspto.gov/) around the world.
Tobacco and Smoking Cessation Technology
The World Health Organization estimates there are one billion smokers in the world and six million people die every year from complications due to smoking.
22nd Century Group, Inc., provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. The company’s products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine.
In 2016, 22nd Century was the beneficiary of tens of millions of dollars of clinical trials that were primarily funded by the National Institute of Health (NIH) and the U.S. Food and Drug Administration (FDA). Based on these and previous independent clinical trials, countries around the world have identified likely paths to integrate 22nd Century’s VLN tobacco products as an ingredient in their respective tobacco control policies.
XXII may be on the verge of changing the tobacco and cannabis market spaces with their technology and products that have the potential to save millions of lives and billions in Healthcare costs. Analysts Chardan Capital Markets, reiterated on March 7th, 2017 a $3.50 price target and a “buy” rating on 22nd Century Group.
Must see Cannabis patent portfolio
Also see Tobacco plant patent’s
Article Source- Traders News Source
Traders News Source Recent Track Record
Traders News Source Mission Statement
We strive to highlight the future potential as well as the inherent risk in each small cap company we cover while remaining neutral as a leading third-party equity research firm.
Disclaimer
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase re-distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure. TNS LLC has not been compensated for this report on XXII.
